McClintock TR, Valovska MTI, Kwon NK, et al. - In this population-based matched cohort study using data sourced from the Military Health System Data Repository of men aged 40–64 years with no former history of urolithiasis who received continuous testosterone replacement therapy (TRT, n = 26,586) for a diagnosis of hypogonadism between 2006 and 2014, experts ascertained whether TRT in men with hypogonadism was related to a progressed risk of urolithiasis. Among those on TRT, in comparison with those who did not undergo this hormonal therapy, an improvement in the 2-year absolute risk of stone events was noted.